Revance Therapeutics Q2 2024 GAAP EPS $(0.36) Beats $(0.53) Estimate, Sales $65.389M Miss $66.061M Estimate
Author: Benzinga Newsdesk | August 08, 2024 04:17pm
Revance Therapeutics (NASDAQ:
RVNC) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.53) by 32.08 percent. The company reported quarterly sales of $65.389 million which missed the analyst consensus estimate of $66.061 million by 1.02 percent. This is a 12.48 percent increase over sales of $58.134 million the same period last year.
Posted In: RVNC